Loading patent…
AssigneeVical Incorporated
InventorsGary G. Hermanson, Andrew J. Geall, Mary Kopke Wloch
Estimating the term…
The invention relates to plasmids operably encoding HCMV antigens, in which the naturally-occurring coding regions for the HCMV antigens have been modified for improved translation in human or other mammalian cells through codon optimization. HCMV antigens, which are useful in the invention include, but are not limited to pp65, glycoprotein B (gB), IE1, and fragments, variants or derivatives of any of these antigens. In certain embodiments, sequences have been deleted, e.g., the Arg435-Lys438 putative kinase in pp65 and the membrane anchor and endocellular domains in gB. The invention is further directed to methods of inducing an immune response to HCMV in a mammal, for example, a human, comprising delivering a plasmid encoding a codon-optimized HCMV antigen as described above. The invention is also directed to pharmaceutical compositions comprising plasmids encoding a codon-optimized HCMV antigen as described above, and further comprising adjuvants, excipients, or immune modulators.
A method of eliciting an immune response to human cytomegalovirus (CMV) in a human or in a human tissue comprising administering an isolated polynucleotide comprising SEQ ID NO:5, or an isolated polynucleotide comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO:6 to the human or human tissue.
A method of eliciting an immune response to human cytomegalovirus (CMV) in a human or in a human tissue comprising administering a composition comprising:
Dependencies are inferred from the claim text.